Tuftsin
目录号 : GC31700A phagocytosis-stimulating peptide
Cas No.:9063-57-4
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Tuftsin is an endogenous peptide generated by proteolysis of leukokinin that stimulates phagocytosis.1 It binds human polymorphonuclear leukocytes (PMN), human monocytes, and mouse macrophages with Kd values of 130, 125, and 53 nM, respectively.2 Tuftsin (200 nM) increases phagocytosis of IgG-coated ovine red blood cells by 61% in isolated mouse peritoneal macrophages. It increases phagocytosis of the bacteria S. aureus and L. monocytogenes, as well as the fungus S. oviformis, by isolated human, mouse, rabbit, dog, or guinea pig phagocytes when used at concentrations ranging from 0.01 to 0.15 ?g/ml.3 Tuftsin (0.1, 0.5, and 25 mg/kg) increases survival in a syngeneic mouse model of 2-methylcholanthrene-induced fibrosarcoma.4
1.Najjar, V.A., and Nishioka, K."Tuftsin": A natural phagocytosis stimulating peptideNature228(5272)672-673(1970) 2.Gottlieb, P., Stabinsky, Y., Hiller, T., et al.Tuftsin receptorsAnn. N. Y. Acad. Sci.41993-106(1983) 3.Martinez, J., and Winternitz, F.Bactericidal activity of tuftsinMol. Cell Biochem.41123-136(1981) 4.Catane, R., Schlanger, S., Weiss, L., et al.Toxicology and antitumor activity of tuftsinAnn. N. Y. Acad. Sci.419251-260(1983)
Cas No. | 9063-57-4 | SDF | |
Canonical SMILES | Thr-Lys-Pro-Arg | ||
分子式 | C21H40N8O6 | 分子量 | 500.59 |
溶解度 | Water : ≥ 160 mg/mL (319.62 mM) | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.9976 mL | 9.9882 mL | 19.9764 mL |
5 mM | 0.3995 mL | 1.9976 mL | 3.9953 mL |
10 mM | 0.1998 mL | 0.9988 mL | 1.9976 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
[Tuftsin]
Literature review. The tetrapeptide tuftsin (Thr-Lys-Pro-Arg) is cleaved off the carrier IgG molecule enzymatically and stimulates the phagocytic and bactericidal activity of polymorphonuclear leucocytes and macrophages. The action of tuftsin is mediated by specific receptor sites on the surface of these cells. Its antitumor activity has been shown in vitro as well as in vivo. The influence of tuftsin on the major metabolic processes of the cell (hexosemonophosphate shunt; cAMP/cGMP; Ca++-distribution; redox reactions) is the basis of its mode of action.--The feature of tuftsin and its low toxicity make it a useful agent for immunotherapy.
Tuftsin - Properties and Analogs
Background: Immunomodulation is one of the significant therapeutic strategies. It includes both stimulation and suppression of the immune system by a variety of substances called immunomodulators, designed to regulate the immune response of the organism against infections of varying etiology. An example of such a substance is tuftsin (TKPA) 3 (Fig. (1)). In this paper were included tuftsin derivatives, which were described over the years, their together with biological activity and clinical potential.
Methods: We reviewed a bibliographic database to gather all the important information about the tuftsin peptide. We have delineated the significant information on the activity of the tetrapeptide itself and its derivatives. Analogs were divided because of their anti-tumor, anti-inflammatory, antimicrobial and anti-viral activity.
Results: This paper describes eighty-six documents. Thirty-two of them concern on activity of tuftsin in the human organism. The remaining fifty-four describe peptide analogues and their properties, including eleven papers about the tuftsin-based peptides contained in the vaccines, nine papers representing anticancer activity of the tuftsin derivatives, twenty-six about antiinflammatory compounds, and five papers describing the antitumor activity of the tuftsin analogs.
Conclusion: The findings of this review confirm the importance of the tuftsin and their derivatives. Most of these substances showed anti-tumor, anti-inflammatory or antibacterial activities. A large amount of the compounds may find use in vaccines. Tuftsin can also be used to prepare fusion proteins in the treatment of cancer and as carriers of many biologically active substances.
Tuftsin: A Natural Molecule Against SARS-CoV-2 Infection
Coronavirus disease 2019 (COVID-19) continuously progresses despite the application of a variety of vaccines. Therefore, it is still imperative to find effective ways for treating COVID-19. Recent studies indicate that NRP1, an important receptor of the natural peptide tuftsin (released from IgG), facilitates SARS-CoV-2 infection. Here, we found 91 overlapping genes between tuftsin targets and COVID-19-associated genes. We have demonstrated that tuftsin could also target ACE2 and exert some immune-related functions. Molecular docking results revealed that tustin could combine with ACE2 and NRP1 in stable structures, and their interacted regions cover the binding surfaces of S1-protein with the two receptors. Using surface plasmon resonance (SPR) analysis, we confirmed that tuftsin can bind ACE2 and NRP1 directly. Importantly, using SPR-based competition assay we have shown here that tuftsin effectively prevented the binding of SARS-CoV-2 S1-protein to ACE2. Collectively, these data suggest that tuftsin is an attractive therapeutic candidate against COVID-19 and can be considered for translational as well as clinical studies.
Tuftsin phosphorylcholine-a novel compound harnessing helminths to fight autoimmunity
The distinction that in areas where helminthic infections are common, autoimmune diseases are less prevalent, led to the investigation of immune modulatory properties of helminths and their derivatives. Such are phosphorylcholine (PC) moieties which are a component of secreted products of helminths. PC has been broadly studied for its attenuating effects on the human immune system. In an attempt to develop a novel therapeutic small molecule for the treatment of autoimmune conditions, we have conjugated PC with tuftsin, a natural immunomodulatory tetrapeptide, to create TPC. Herein, we review our findings regarding the effects of TPC in murine models of three autoimmune diseases-systemic lupus erythematosus (SLE), inflammatory bowel disease (IBD), and rheumatic arthritis (RA), as well as ex-vivo samples from giant cell arteritis (GCA) patients. In all four disease models examined, TPC was shown to attenuate the inflammatory response by reducing expression of pro-inflammatory cytokines and altering the phenotype of T cell expression. In murine models, TPC has further produced a significant improvement in clinical disease scores with no significant side effects noted. Our findings suggest TPC presents promising potential as a novel therapeutic agent for the effective treatment of various autoimmune conditions.
Targeted Drug Delivery Using Tuftsin-bearing Liposomes: Implications in the Treatment of Infectious Diseases and Tumors
Tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg), acts as an immunopotentiating molecule with its ability to bind and activate many immune cells, including macrophages or monocytes, neutrophils and dendritic cells. The specific targeting activity of tuftsin has been further increased by its palmitoylation followed by its incorporation into the lipid bilayer of liposomes. Tuftsin-bearing liposomes (Tuft-liposomes) possess several characteristics that enable them to act as a potential drug and vaccine carriers. Tuft-liposomes-loaded anti-microbial drugs have been shown to be highly effective against many infectious diseases, including tuberculosis, leishmaniasis, malaria, candidiasis and cryptococosis. Moreover, Tuft-liposomes also increased the activity of anticancer drug etoposide against fibrosarcoma in mice. Tuft-liposomes showed the immune-potentiating effect and rejuvenated the immune cells in the leukopenic mice. In addition, antigens encapsulated in Tuftsin-bearing liposomes demonstrated greater immunogenicity by increasing the T cell proliferation and antibody secretion. Keeping into consideration their specific targeting and immunopotentiating effects, Tuft-liposomes may potentially be used as promising drug and vaccine delivery systems.